Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORDELIA: Deferasirox vs Deferoxamine in Cardiac Iron Overload
NCT00600938Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of deferasirox in iron overload (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Myocardial T2* at 12 months. Started Nov 2007; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT00600938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600938.